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that CZP+MTX seems to be a cost-effective alternative when compared to approved 
subcutaneous anti-TNFs for the management of RA in Greece.
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Objectives: Osteoporotic fractures are common in older adults and are often asso-
ciated with high morbidity and mortality. As the incidence increases with age, it 
is natural that osteoporotic fractures have become a major health problem world-
wide. Increasing number of patients with osteoporotic fracture will have a serious 
economic impact on the patient themselves and the society. The objective of 
this study is to study the cost-effectiveness of strontium ranelate compared 
to alendronate for patients with post-menopausal osteoporotic fractures in 
Malaysia. MethOds: A Markov model was developed to project clinical and eco-
nomic benefits of strontium in a hypothetical cohort of patients (N= 1,000) over a 
5-year time horizon. This study was conducted from a payer perspective. Model 
parameters including transition probabilities and costs of treating fracture at vari-
ous sites were Malaysia-specific. Drug costs were obtained from a public teach-
ing hospital in Kuala Lumpur. Utilities were derived from previous literatures and 
efficacy data were derived from two pivotal trials, i. e. SOTI and TROPOS trials. 
Outcomes were presented as cost per quality-adjusted life year (QALY) gained. A 
discount rate of 3% was applied. Both 1-way and multivariate probabilistic sen-
sitivity analyses were undertaken to evaluate robustness of results. Results: 
Compared to alendronate, strontium could prevent 328 wrist, 192 hip, 7 vertebra 
and 115 multiple fractures respectively over 5 years, which was translated into 
27.9 QALYs gained. Using strontium can lead to cost reduction of MYR1,416,595 
(USD442,685), MYR478,257 (USD149,455), MYR22,784 (USD7,120) and MYR61,883 
(USD113,088) due to reduced episodes of fractures at wrist/hip/vertebra/multi-
ple sites respectively. The total reduction of direct medical costs of MYR2,279,519 
(USD712,349) was larger than the extra drug cost, hence making strontium a cost-
saving therapy. cOnclusiOns: It was shown that strontium appeared to be more 
cost-effective compared to alendronate and hence should be recommended in the 
public sector in Malaysia.
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Objectives: To evaluate the cost-effectiveness of MabThera in patients with severe 
GPA and MPA in the United Kingdom (UK). bAckgROund: In March 2014 NICE 
issued positive guidance for the use of MabThera in patients with severe GPA and 
MPA [TA 308]. MethOds: An economic model was developed to reflect the health 
care system and the current treatment pathway in the UK. The cost-effectiveness 
analysis employs a Markov model with four health states: complete remission, 
non- remission, uncontrolled disease and death. Patients were assumed to start in 
the non-remission health state, transitioning based on their response to treatment. 
Relapsing patients who have exhausted all available treatment options they are 
assumed to enter the uncontrolled disease health state where they remain until 
death. The efficacy data for the intervention and comparator arm were taken from 
the RAVE study (Stone et al 2010) which demonstrated that MabThera was non-
inferior to cyclophosphamide (CYC). In a subgroup of patients who had received 
prior therapy, MabThera was superior to CYC. Benefits were expressed as QALYs. 
Costs were calculated from a National Health Service and Personal Social Services 
perspective. The analysis calculated incremental costs and benefits associated with 
the addition of MabThera to the treatment paradigm which was assumed to consist 
of CYC and azathioprine. For patients intolerant to CYC, MabThera was assumed to 
substitute for CYC. The RAVE trial reports health related quality of life using SF-36. 
The SF-36 scores were converted to EQ-5D in a post-hoc analysis using a published 
model [Ara and Brazier 2008]. Results: Base case results estimated incremental 
costs of approximately £3,700 and incremental QALYs of 0.306. The incremental 
cost-effectiveness ratio (ICER) was £12,100 per QALY gained. cOnclusiOns: The 
results of this analysis suggest that MabThera is a cost-effective treatment for severe 
GPA and MPA.
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Objectives: To assess the indirect costs of RA, CD and Ps in an employed population 
in Poland. MethOds: Data on presenteeism and absenteeism related with analyzed 
diagnoses were collected in a cross-sectional study from patients of ambulatory 
specialist care around Poland (30 rheumatology, 30 dermatology and 29 gastroenter-
ology centers). Lost productivity was measured with Work Productivity and Activity 
Impairment (WPAI) questionnaire and patients’ disease activity was assessed on 
standardized, disease specific scales (DAS28, PASI, and CDAI). 328 (RA), 460 (Ps), 256 
(CD) working patients were included in the analyses conducted separately for each 
diagnosis. Unit cost of lost productivity was estimated using 2012 GDP per worker 
per hour corrected for diminishing marginal productivity and added up to PLN 
33.18. Results: Mean age of M2W respondents was 36 for CD, 42 for Ps and 46 for 
RA patients (only patients in productive age – 18-60/65 were included in the study). 
Objectives: A tailored accelerated physiotherapy (AP) program following 
Resurfacing Hip Arthroplasty (RHA) has been shown to be effective in improving hip 
function and range of motion in young male patients; however no evidence has been 
provided on its cost-effectiveness. The aim of this UK trial-based economic evalu-
ation was to assess the cost-effectiveness of AP versus a standard rehabilitation 
protocol (SRP). MethOds: Trial participants were randomized post-RHA to AP or 
SRP. The experimental arm followed an 8-week programme with no hip precautions, 
full-weight bearing from day one, tailored exercises and an additional physiotherapy 
session. The control group received the standard 8-week course of rehabilitation. At 
6, 16, and 52 weeks, patients reported primary and secondary health care contacts, 
use of equipment, and private health care contacts. These data were valued using 
2012/2013 national average unit costs. The 3-level EuroQol EQ-5D questionnaire was 
completed by patients at baseline, 6, 16 and 52 weeks and used to calculate Quality 
Adjusted Life Years (QALYs) to 12 months. Results: 80 young males (median age: 
55.8 years) were randomized to AP (n= 40) or SRP (n= 40). Preliminary results showed 
mean (SE) health care costs to 52 weeks were £375 (£76) in the AP arm and £612 (£150) 
in the SRP arm (mean (95% CI) difference -£237 (-£582 to £108)). There were more 
visits to secondary care and primary care practitioners in the SRP arm. Mean (SE) 
QALYs were 0.84 (0.02) with AP and 0.72 (0.03) with SRP (mean (95% CI) difference 
0.12 (0.04 to 0.21)). The probability that AP is cost-effective at a maximum willing-
ness to pay of £20,000 per QALY is 99%. cOnclusiOns: From the perspective of the 
health care provider, a tailored accelerated physiotherapy programme for younger 
male patients undergoing RHA appears cost-effective when compared to a standard 
rehabilitation programme.
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Objectives: The aim of this study is evaluation of the effectiveness and cost-
effectiveness of using rituximab as first line of treatment for patients with refrac-
tory rheumatoid arthritis in comparison to continuing conventional DMARDs, 
from a perspective of health service governors. MethOds: A systematic review 
was implemented through searching PubMed, Scopus and Cochrane Library. 
Quality assessment was performed by JADAD questionnaire. After meta-analysis 
of ACR (American College of Rheumatology) index results, QALY (Quality Adjusted 
Life Years) gained were calculated through mapping ACR index to HAQ (Health 
Assessment Questionnaire) and utility index. To measure the direct and indirect 
medical costs, a set of interviews with patients were applied. Thirty two patients 
were selected from three referral rheumatology clinics in Tehran with definite diag-
nosis of refractory rheumatoid arthritis one year before, and treatment regimen of 
either rituximab or DMARDs within last year. Incremental cost-effectiveness ratio 
were calculated for a period of six months for base case and generic rituximab 
scenario. Three fold of GDP (Gross Domestic Product) per capita was considered as 
threshold of cost-effectiveness. Results: Four studies were eligible to be consid-
ered in this systematic review. Total risk difference of 0.3 for ACR20 criteria, 0.21 
for ACR50 and 0.1 for ACR70 were resulted from meta-analysis. Also mean of total 
medical costs of patients for 24 weeks were $3985 in rituximab group and $932 for 
DMARDs group in the base case analysis. Thus, the incremental cost per QALY ratio 
will be $45900 to $70223 in the base case, and $32386 to $49550 for generic scenario, 
while the threshold of cost-effectiveness was $21684. cOnclusiOns: Rituximab 
cannot be considered as cost-effective for the treatment of patients with refractory 
rheumatoid arthritis in Iran.
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Objectives: To evaluate the cost-effectiveness of certolizumab pegol (CZP) as an 
add-on therapy to methotrexate (MTX) versus etanercept, adalimumab or goli-
mumab in patients with moderate-to-severe active rheumatoid arthritis (RA) who 
did not respond adequately to conventional synthetic disease-modifying anti-rheu-
matic drugs (csDMARDs) including MTX in Greece. MethOds: A Markov model 
with a cycle length of 6 months was used to assess cost and health outcomes of 
CZP versus other TNF-α inhibitors recommended in Greece over a patient’s lifetime. 
On the discontinuation of first-line treatment with CZP or comparator, patients 
were switched to a second anti-TNF agent, and after failing that, they moved on to 
a third biologic agent with another mode of action. A sequential use of csDMARDs 
was assigned after the last biologic therapy. Clinical data and utility values were 
extracted from published literature. The analysis was conducted from a third-party 
payer perspective in Greece. Costs related to drug acquisition, administration, moni-
toring and patient management were considered (2014). All results were presented 
as incremental cost-effectiveness ratios (ICERs) per quality-adjusted life year (QALY). 
Probabilistic sensitivity analysis (PSA) was performed to ascertain the robustness of 
the base-case findings. Results: The base-case analysis indicated that compared 
with etanercept+MTX, CZP+MTX was cost-effective (ICER: € 3,177/QALY), and versus 
adalimumab or golimumab, CZP was the dominant strategy (less costly and more 
effective). For all comparisons, CZP treatment resulted in greater improvements in 
life expectancy and QALYs. PSA indicated that at the willingness-to-pay threshold 
of € 34,000 per QALY gained, CZP+MTX was associated with a 71.6%, 97.9% or 99.2% 
probability of being cost-effective versus etanercept, golimumab or adalimumab as 
combination therapies with MTX, respectively. cOnclusiOns: This analysis shows 
